AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15888425 — intervention group
Group type: COMPARATOR
Intervention: Vocational rehabilitation alone
Number of subjects: 138
Study 14519564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatehouse Project intervention
Number of subjects: 26
Study 10085281 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical crude honey (12 hourly application)
Number of subjects: 50
Study 10085281 — intervention group
Group type: COMPARATOR
Intervention: Local antiseptics (70% Ethanol and povidone-iodine)
Number of subjects: 50
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy plus CAF (O+CAF)
Number of subjects: 147
Study 7751892 — intervention group
Group type: COMPARATOR
Intervention: CAF (Cyclophosphamide, Doxorubicin, and Fluorouracil)
Number of subjects: 147
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > or = 45 years
Number of subjects: 147
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: Last menstruation within 1 month
Number of subjects: 147
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: O+CAF in patients < 45 years
Number of subjects: 147
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF in patients > 45 years
Number of subjects: 147
Study 7751892 — intervention group
Group type: EXPERIMENTAL
Intervention: O+CAF in PS O patients
Number of subjects: 147
Study 2264899 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with intravenous sedation (fentanyl, midazolam, or combinations thereof)
Number of subjects: 500
Study 2264899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl, midazolam, and fentanyl/midazolam combinations as intravenous supplements
Number of subjects: 500
Study 6449360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin (6 g/m(2) . 6 h) plus sisomicin (45 g/m2 . 6 h)
Number of subjects: 22
Study 6449360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 g/m2 . 6 h) plus sisomicin (45 g/m2 . 6 h)
Number of subjects: 22
Study 6449360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both combinations
Number of subjects: 22
Study 6449360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 22
Study 30447958 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-ppm nitric oxide (NO) added to the CPB circuit during cardiac surgery
Number of subjects: 60
Study 30447958 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard CPB protocol without NO)
Number of subjects: 60
Study 26538521 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + moxifloxacin (MOX)
Number of subjects: 40
Study 26538521 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 40
Study 25615542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic assessment of morphological awareness
Number of subjects: 54
Study 23751300 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based computerized cognitive remediation program for 12 weeks
Number of subjects: 23
Study 23751300 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched children with 22q11DS)
Number of subjects: 23
Study 21053091 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario of a highly accurate screening test (sensitivity 99% and specificity 99%) with manipulated prevalence (1%, 2%, 10%, 25%, 95%, or no information)
Number of subjects: 1361
Study 21053091 — intervention group
Group type: COMPARATOR
Intervention: No information on prevalence
Number of subjects: 1361
Study 19250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia patient education program
Number of subjects: 270
Study 16459230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/d of PSE in DAG-containing mayonnaise
Number of subjects: 0
Study 16459230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/d of PSE in DAG-containing mayonnaise
Number of subjects: 0
Study 15383884 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique for autologous fat harvesting
Number of subjects: 30
Study 11298175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) (group 2)
Number of subjects: 142
Study 11298175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 3)
Number of subjects: 142
Study 11298175 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 1)
Number of subjects: 142
Study 11298175 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) (group 4)
Number of subjects: 142
Study 11298175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) (groups 2 and 3)
Number of subjects: 142
Study 9392406 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 microg thrice daily for 14 days)
Number of subjects: 8
Study 9392406 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (600 microg single inhalation after 14 days treatment)
Number of subjects: 8
Study 9392406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (thrice daily for 14 days)
Number of subjects: 8
Study 8017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1 b.w.)
Number of subjects: 30
Study 8017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg.kg‐1 b.w.)
Number of subjects: 30
Study 8017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg.kg‐1 b.w.)
Number of subjects: 30
Study 8017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam and fentanyl (0.005 mg.kg‐1 b.w.)
Number of subjects: 30
Study 8017589 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.4‐0.8 Vol%)
Number of subjects: 30
Study 2465099 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antiarrhythmic therapy (various drugs including encainide and flecainide)
Number of subjects: 502
Study 2465099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 2465099 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide and flecainide treatments
Number of subjects: 502
Study 2465099 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapies (general)
Number of subjects: 502
Study 62111 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium (doses aimed at maintaining a 'Thrombotest' value of 10%, given from the day of admission until independent mobility or for 3 months)
Number of subjects: 160
Study 62111 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 160
Study 31444192 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-B programme (high-intensity interval training, exercise counselling + guidance, home-based exercise support using information and communication technology, and a wearable device)
Number of subjects: 0
Study 31444192 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual with a wearable device
Number of subjects: 0
Study 27155315 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO-MetS
Number of subjects: 7932
Study 27155315 — intervention group
Group type: EXPERIMENTAL
Intervention: IDF-MetS
Number of subjects: 7932
Study 27155315 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7932
Study 27155315 — intervention group
Group type: COMPARATOR
Intervention: IDF
Number of subjects: 7932
Study 27155315 — intervention group
Group type: COMPARATOR
Intervention: JIS
Number of subjects: 7932
Study 27155315 — intervention group
Group type: COMPARATOR
Intervention: WHO
Number of subjects: 7932
Study 26279111 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment (1.6 µg/kg daily)
Number of subjects: 59
Study 26279111 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 59
Study 26279111 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 59
Study 23430723 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific antibiotics (Group A)
Number of subjects: 471
Study 23430723 — intervention group
Group type: COMPARATOR
Intervention: No specific antibiotics (Group B)
Number of subjects: 471
Study 23430723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 471
Study 21208086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-containing dentifrice (AloeDent)
Number of subjects: 16
Study 21208086 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice (Sensodyne Mint)
Number of subjects: 16
Study 20035686 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 0
Study 18257346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking blood therapy combined with acupuncture
Number of subjects: 240
Study 18257346 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine (Aciclovir plaster and Aciclovir tablets)
Number of subjects: 240
Study 15096431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine hydrochloride with epinephrine
Number of subjects: 130
Study 15096431 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (placebo)
Number of subjects: 130
Study 11495138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dental gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 122
Study 11495138 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 122
Study 9728853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihistamines (diphenhydramine ≤ 1 mg/kg and cimetidine ≤ 4 mg/kg)
Number of subjects: 30
Study 9728853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7802180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal detector device
Number of subjects: 29
Study 3281703 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar bath
Number of subjects: 11
Study 3281703 — intervention group
Group type: COMPARATOR
Intervention: Oil emulsion bath
Number of subjects: 11
Study 29663959 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (4FDC)
Number of subjects: 20
Study 29663959 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-drug fixed-dose combination (2FDC)
Number of subjects: 20
Study 29663959 — intervention group
Group type: COMPARATOR
Intervention: Single-drug reference
Number of subjects: 20
Study 28685558 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine + Silymarin (BBR)
Number of subjects: 136
Study 28685558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25772742 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent implantation in group A (BMS restenosis)
Number of subjects: 32
Study 25772742 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in group B (de novo atherosclerotic lesions)
Number of subjects: 32
Study 25772742 — intervention group
Group type: COMPARATOR
Intervention: DES struts protruding out of BMS in group A
Number of subjects: 32
Study 23890459 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 12
Study 23890459 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 21060780 — intervention group
Group type: EXPERIMENTAL
Intervention: H1N1 LAIV (live attenuated influenza vaccine)
Number of subjects: 626
Study 21060780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study 18663427 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (7 weeks)
Number of subjects: 70
Study 18663427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 70
Study 16801670 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of dementia in patients with Lewy body dementia (LBD)
Number of subjects: 0
Study 16801670 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of dementia in patients with Alzheimer's disease (AD)
Number of subjects: 0
Study 16801670 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 14499320 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as monotherapy (n=7) or adjunctive therapy to carbamazepine (CBZ) (n=2) at dosages ranging from 25 mg to 100 mg twice daily
Number of subjects: 9
Study 14499320 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 9
Study 10707873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 microg/kg b.w. rHuIL-12
Number of subjects: 46
Study 10707873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg/kg b.w. rHuIL-12
Number of subjects: 46
Study 10707873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 microg/kg b.w. rHuIL-12
Number of subjects: 46
Study 10707873 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 (all doses)
Number of subjects: 46
Study 10707873 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-12 (higher doses)
Number of subjects: 46
Study 9236473 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires with positive rating on the left side
Number of subjects: 140
Study 9236473 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires with positive rating on the right side
Number of subjects: 140
Study 9236473 — intervention group
Group type: EXPERIMENTAL
Intervention: Forms with five, six, or seven response options
Number of subjects: 140
Study 7934094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass (group I)
Number of subjects: 15
Study 7934094 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass (group II)
Number of subjects: 15
Study 3259084 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 3259084 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 40
Study 29532591 — intervention group
Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 1115
Study 29532591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115
Study 28459732 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 128
Study 28459732 — intervention group
Group type: COMPARATOR
Intervention: Control group (fluid therapy based on traditional principles)
Number of subjects: 128
Study 26242578 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily, increased to 1000 mg twice daily over 6 weeks)
Number of subjects: 100
Study 26242578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg daily)
Number of subjects: 100
Study 26242578 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study 24045239 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 54
Study 21690510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray, 55 μg/nostril daily for 2 weeks
Number of subjects: 24
Study 21690510 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 18581467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541
Study 18581467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 17205943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus epidural injection of 80 mg methylprednisolone and 10 mg bupivacaine
Number of subjects: 598
Study 17205943 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (oral antiviral agents and analgesics) alone
Number of subjects: 598
Study 14610642 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 66
Study 14610642 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (Premarin 0.625 mg/day, and Provera 2.5 mg/day)
Number of subjects: 66
Study 14610642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 10734271 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 152
Study 10734271 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 152
Study 10734271 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 152
Study 9366539 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 10
Study 9366539 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological evaluation
Number of subjects: 10
Study 9366539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function tests
Number of subjects: 10
Study 9366539 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs
Number of subjects: 10
Study 1550312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol DA‐20 per cent (blood substitute)
Number of subjects: 47
Study 2890150 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg at night)
Number of subjects: 9
Study 2890150 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 9
Study 2890150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg at night)
Number of subjects: 9
Study 2890150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2890150 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (Famotidine and Ranitidine)
Number of subjects: 9
Study 30587165 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin administration
Number of subjects: 106
Study 30587165 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 106
Study 27841968 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) applied at 10 points through the surgical scar in three sessions.
Number of subjects: 85
Study 27841968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (disabled laser) applied at the same points and sessions as LLLT.
Number of subjects: 85
Study 23458566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremoval of abutments during surgery (one abutment at one time test protocol)
Number of subjects: 68
Study 23458566 — intervention group
Group type: COMPARATOR
Intervention: Control group (removal of abutments and standard prosthetic protocol)
Number of subjects: 68
Study 22534479 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS treatment
Number of subjects: 120
Study 22534479 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+MARS treatment
Number of subjects: 120
Study 20862935 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on Quchi (LI 11) and Taichong (LR 3)
Number of subjects: 60
Study 20862935 — intervention group
Group type: COMPARATOR
Intervention: Western medication (Captopril)
Number of subjects: 60
Study 18187817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg twice daily for the first month and 200 mg once daily for the next month (total duration 2 months)
Number of subjects: 117
Study 18187817 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 250 mg twice daily for the first month and 250 mg once daily for the next month (total duration 2 months)
Number of subjects: 117
Study 15679621 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/day
Number of subjects: 31
Study 15679621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12940470 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years Program (PDFY)
Number of subjects: 429
Study 12940470 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 429
Study 10485271 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered 2 h before cyclophosphamide (CP)
Number of subjects: 10
Study 10485271 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-alpha) administered 24 h after cyclophosphamide (CP)
Number of subjects: 10
Study 7815355 — intervention group
Group type: COMPARATOR
Intervention: LTB4 (3 ng/site)
Number of subjects: 22
Study 7815355 — intervention group
Group type: COMPARATOR
Intervention: LTB4 (10 ng/site)
Number of subjects: 22
Study 7815355 — intervention group
Group type: COMPARATOR
Intervention: LTB4 (30 ng/site)
Number of subjects: 22
Study 7815355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 10(-9) mol/site)
Number of subjects: 22
Study 7815355 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (oral)
Number of subjects: 22
Study 7815355 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap (oral)
Number of subjects: 22
Study 1657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg)
Number of subjects: 48
Study 1657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg)
Number of subjects: 48
Study 1657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg)
Number of subjects: 48
Study 1657084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7104466 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dose of chlorothiazide
Number of subjects: 8
Study 7104466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dose of chlorothiazide
Number of subjects: 8
Study 7104466 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg dose of chlorothiazide
Number of subjects: 8
Study 31801510 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closed-suction drain (non-CSD)
Number of subjects: 32
Study 31801510 — intervention group
Group type: COMPARATOR
Intervention: Closed-suction drain (CSD)
Number of subjects: 32
Study 29030775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment for three cycles of 21 days
Number of subjects: 241
Study 29030775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 241
Study 29030775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone treatment)
Number of subjects: 241
Study 24755773 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based home training (e-Training)
Number of subjects: 18
Study 24755773 — intervention group
Group type: COMPARATOR
Intervention: Hippotherapy
Number of subjects: 18
Study 23560500 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 72
Study 23560500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22518827 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM capsazepine
Number of subjects: 12
Study 22518827 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM l‐NAME
Number of subjects: 12